Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutic Pipeline Market Review, H2 2016

Thursday, September 22, 2016 4:50
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutic Market 2016

Complete Report Details @ https://www.wiseguyreports.com/reports/649778-chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-review-h2-2016

The, ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H2 2016’, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.

For more information or any query mail at sales@wiseguyreports.com

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/649778-chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 
- The report reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics and enlists all their major and minor projects 
- The report assesses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents – Major Key Points

#Companies Involved in Therapeutics Development:

CSL Limited 13 
GeNeuro SA 14 
Mitsubishi Tanabe Pharma Corporation 15 
Octapharma AG 16 
Pfizer Inc. 17 
Shire Plc 18 
Teijin Pharma Limited 19 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Therapeutics Assessment 20 
Assessment by Monotherapy Products 20 
Assessment by Combination Products 21 
Assessment by Target 22 
Assessment by Mechanism of Action 24 
Assessment by Route of Administration 25 
Assessment by Molecule Type 27 
Drug Profiles 29 
(hyaluronidase (human) (recombinant) + immune globulin (human)) – Drug Profile 29 
Product Description 29 
Mechanism Of Action 29 
R&D Progress 29 
fingolimod hydrochloride – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
GL-2045 – Drug Profile 39 
Product Description 39 
Mechanism Of Action 39 
R&D Progress 39 
GNbAC-1 – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 

…….CONTINUED

For more information or any query mail at sales@wiseguyreports.com

Get Exclusive Discount On This Report @ https://www.wiseguyreports.com/check-discount/649778-chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-review-h2-2016

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.